Seer, Inc. Stock price

Equities

SEER

US81578P1066

Office Equipment

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
1.54 USD -1.91% Intraday chart for Seer, Inc. -6.67% -20.62%
Sales 2023 * 16.42M Sales 2024 * 19.7M Capitalization 98.29M
Net income 2023 * -92M Net income 2024 * -77M EV / Sales 2023 * -13 x
Net cash position 2023 * 312M Net cash position 2024 * 274M EV / Sales 2024 * -8.93 x
P/E ratio 2023 *
-1.06 x
P/E ratio 2024 *
-1.12 x
Employees 164
Yield 2023 *
-
Yield 2024 *
-
Free-Float 87.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.91%
1 week-6.67%
Current month-10.47%
1 month-8.33%
3 months-9.41%
6 months-37.14%
Current year-20.62%
More quotes
1 week
1.53
Extreme 1.53
1.66
1 month
1.51
Extreme 1.51
1.87
Current year
1.51
Extreme 1.51
2.00
1 year
1.46
Extreme 1.455
6.18
3 years
1.46
Extreme 1.455
57.87
5 years
1.46
Extreme 1.455
86.55
10 years
1.46
Extreme 1.455
86.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-03-15
Director of Finance/CFO 56 20-04-30
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 17-11-30
Founder 75 17-03-15
Director/Board Member 57 18-01-31
More insiders
Date Price Change Volume
24-02-23 1.54 -1.91% 323,427
24-02-22 1.57 0.00% 623,705
24-02-21 1.57 0.00% 436,174
24-02-20 1.57 -4.85% 846,115
24-02-16 1.65 -1.20% 351,612

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a gateway to the proteome. The Company's initial product, the Proteograph Product Suite (Proteograph), is an integrated solution that includes engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. Proteograph leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. Its engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide level, including protein variants. It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product suite and is selling and marketing the Proteograph for research use only (RUO).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.54 USD
Average target price
7 USD
Spread / Average Target
+354.55%
Consensus
  1. Stock
  2. Equities
  3. Stock Seer, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer